AORT Form 4: Holloway Exercises Options, Sells 23,356 Shares
Jean F. Holloway, SVP and General Counsel of Artivion, Inc. (AORT), reported securities transactions dated 08/12/2025.
Rhea-AI Filing Summary
Jean F. Holloway, SVP and General Counsel of Artivion, Inc. (AORT), reported securities transactions dated 08/12/2025. She exercised stock options covering 16,975 underlying shares with a conversion/exercise price of $26.24 (option grant dated 02/19/2021, vesting 33 1/3% per year and first exercisable on 02/19/2021). On the same date she sold 16,975 shares at a weighted-average price of about $43.011 and an additional 6,381 shares at about $43.018. The filings show her beneficial ownership moved from 195,485 shares to 178,510 and then to 172,129 shares following the reported transactions. Footnotes disclose the weighted-average sale price ranges and offer to provide per-price details on request.
Positive
- Exercised vested options converting 16,975 option shares into common stock at a conversion price of $26.24.
- Disclosure includes vesting and expiration details (grant date 02/19/2021, vesting 33 1/3% annually, expiration 02/19/2027) and weighted-average sale price ranges.
Negative
- Insider sold 23,356 shares on 08/12/2025 (16,975 and 6,381 shares) at weighted-average prices of about $43.011 and $43.018, reducing beneficial ownership to 172,129 shares.
- Substantial same-day disposition of shares acquired by exercise is reported, lowering the reporting person's holdings.
Insights
TL;DR: Insider exercised vested options then executed same-day sales, netting proceeds while reducing holdings to 172,129 shares.
The Form 4 documents an exercise of options for 16,975 shares at a $26.24 conversion price and contemporaneous sales totaling 23,356 shares at weighted-average prices around $43.01 on 08/12/2025. The filings provide sequential beneficial-ownership counts that fall to 172,129 shares after the transactions. The disclosure includes weighted-average price ranges for the sales, with an offer to provide per-price detail on request. From a market-impact perspective the filing is a clear, routine insider reporting of option exercise and share disposition.
TL;DR: Form 4 shows compliant insider disclosure of option exercise, vesting terms, and subsequent sales; no additional governance exceptions noted.
The report identifies Holloway as an officer (SVP, General Counsel) and supplies option vesting information (33 1/3% annually, grant date 02/19/2021) and option expiration date (02/19/2027). The filing is signed and includes explanatory footnotes about weighted-average sale prices and ranges. The form does not assert other arrangements in the visible text. This appears to be standard Section 16 reporting rather than a governance event.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option(Right to Buy) | 16,975 | $0.00 | $0.00 |
| Exercise | Common Stock | 16,975 | $26.24 | $445K |
| Sale | Common Stock | 16,975 | $43.011 | $730K |
| Sale | Common Stock | 6,381 | $43.018 | $274K |
Footnotes (3)
- F1. Reflects weighted average price. Range of prices were between $42.14 to $43.65. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2. Reflects weighted average price. Range of prices were between $42.12 to $43.62. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 19, 2021.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Jean F. Holloway report on the AORT Form 4?
How did Holloway's beneficial ownership change after the transactions?
What are the option vesting and expiration details disclosed?
Were the sale prices reported as exact or weighted averages?
Does the Form 4 indicate the transactions were part of a 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.